Pfizer

Twenty-five years later, the loss still stings. For many of us, that morning changed our lives forever. Our memories have become history to some 100 million Americans too young to remember a day that reshaped the world they live in. Though a generation has gone by, we will always remember. New York has been Pfizer's home since 1849, and we are still just a few miles from where the towers stood. I am heartened that we all continue uniting to honor those we lost, including two of our own, Jean Marie Collin and Joseph "Joe" DeLuca. We remember Jean and Joe alongside the first responders and the thousands of others lost that day. We honor them by making this more than a moment we grieve. Our colleagues across 10 U.S. cities will pack meals for families in need this week, and we also continue our annual support of the 9/11 Memorial & Museum. Through our service, we keep memories alive. And we prove that hate will never overcome compassion, unity and resilience. #NeverForget911

Immunology is the study of the body’s defense system — how it detects, remembers, and helps fight off harmful invaders like viruses and bacteria. Immunology research helps us better understand how our immune system works, paving the way for potential new vaccines, therapies, and immune-targeted treatments. Watch to learn how the immune system works and why studying it is so important. #Innovation #Immunology

Pfizer Canada was pleased to welcome Manitoba Conservative MPs Raquel Dancho (Kildonan—St. Paul), and Grant Jackson (Brandon-Souris) at our manufacturing facility in Brandon, Manitoba. We are proud of Pfizer’s long history in Brandon and the role that Pfizer has in supporting patients, Manitoba’s equine and agricultural communities, and economic contributions across Canada. We appreciated the opportunity to discuss the importance of a strong innovative life sciences sector in Canada.

Halfway through 2026, and Pfizer R&D continues to execute with focus and discipline. Across Oncology, Internal Medicine, Vaccines and Inflammation & Immunology, we advanced critical R&D milestones: achieving approvals, pivotal data readouts, and new study starts. A diverse, deep pipeline, moving forward with purpose. Behind every milestone are years of rigorous science and the relentless work of our teams around the world. It's disciplined execution, sustained across every program and every team, that will keep our pipeline delivering quarter after quarter. Thank you to the Pfizer R&D teams and partners worldwide who are making this happen — every day, for patients everywhere.

Our second quarter results are out today, and I am proud to report another strong quarter of execution. Pfizer's commercial teams showed once again why we are leaders in this industry. Our R&D organization rose to the challenge of an ambitious 2026 plan, with three regulatory approvals, six key data readouts and eight pivotal study starts already achieved. And AI is changing how we work as well, in our laboratories, in our manufacturing plants and in the decisions we make every day. We can accomplish even more for patients, and I am excited about the opportunities ahead in oncology, obesity, vaccines and immunology, where the science is finally catching up to our ambition. Thank you to my colleagues, all of you, for everything behind these results and for your commitment to our purpose. You make me confident in Pfizer's future.

Only in America could a scientist from Greece rise to lead one of the world's great scientific companies. I have never taken that for granted, and I think about it even more as America turns 250. This country has always had a gift for making bold bets that changed the world. The moon landing, the internet, the Human Genome Project. These milestones and so many others came from generations of Americans who chose to invest in science and a belief in a brighter future. Today, America faces a choice once again. New tools in biology, from how we design medicines to how we manufacture them, have already expanded what is possible for patients. AI will shape what comes next in ways we are only beginning to see.  Tools alone don’t determine outcomes. It requires investing in innovation. It requires committing to shaping future opportunities. The coming decade will determine where great new discoveries occur and where the most ambitious scientists build their life's work. I want the answer to be here. Other nations have serious scientific ambition, and I welcome it. Competition never scared America. It has always made us better. You don’t win races by trying to hold others back. You win by running faster, running harder.  America’s opportunity is to continue leading by investing more, building more and moving faster. Pfizer will continue doing its part. We were founded in New York in 1849, and we have been competing and betting on American science ever since. We are driven by a single purpose: delivering breakthroughs that change patients' lives. My wish for America's 250th birthday is simple. Let us choose, once again, to bet on ourselves – and on science. No nation has ever done it better. #A250

Our Chief Scientific Officer, Chris Boshoff, MD, PhD, FMedSci, sat down with Scientific American to reflect on the state of American science and why he's optimistic about what's ahead. https://lnkd.in/dSg3R6q6

Pfizer is advancing our commitment to deliver transformative medicines for people living with cancer through a new strategic global collaboration with Innovent Biologics. Together, we will work to accelerate the research and development of 12 potentially promising early-stage and 𝑑𝑒 𝑛𝑜𝑣𝑜 oncology programs spanning antibody-drug conjugates (ADCs) and multi-specific antibodies with differentiated designs and novel mechanisms. By combining Pfizer Oncology’s global development, regulatory and commercial expertise with Innovent’s scientific discovery and early clinical capabilities, we aim to accelerate the delivery of next-generation breakthroughs for patients in the U.S. and around the world. This collaboration strengthens Pfizer’s Oncology pipeline and supports our long-term ambition to redefine standards of care and help address areas of significant unmet need in cancer treatment.  https://lnkd.in/dXdvQ2cc #Pfizer #Oncology #CancerResearch #Biotech #Innovation